Printer Friendly

QUIDEL RECEIVES U.S PATENT WHICH WILL EXPAND ITS FERTILITY FRANCHISE

QUIDEL RECEIVES U.S PATENT WHICH WILL EXPAND ITS FERTILITY FRANCHISE
 SAN DIEGO, June 17 /PRNewswire/ -- QUIDEL Corp. (NASDAQ: QDEL) today announced the issuance of U.S. Patent No. 5,118,630 (Glaze) for the determination of the infertile period which occurs in women each month.
 This patent forms the underlying foundation of novel birth control diagnostic products from QUIDEL. The company, in collaboration with one of its strategic marketing partners, has its first product SafePlan in U.S. consumer trials. SafePlan(TM) is designed to measure the hormone metabolite pregnanediol glucuronide (PDG) and indicate the safest time to have intercourse without becoming pregnant. SafePlan has distinct advantages over other forms of birth control methods, most notably the lack of chemical side effects associated with oral contraceptives and the possible physical problems seen with intrauterine devices.
 Key applications of technology in the patent include the use of a cycle calendar to optimally identify the fewest days required for testing and the use of immunoassays to detect urinary progesterone metabolites. When concentrations of these hormone metabolites reach or exceed threshold levels, a woman is considered to be in the post- ovulatory infertile period and thus is unlikely to become pregnant.
 "We believe QUIDEL is the only company working on a rapid diagnostic test which will provide women with a method of birth control that is completely non-invasive and comparably reliable," said Scott L. Glenn, chairman and chief executive officer of QUIDEL. "Worldwide there are about 50 million women of child-bearing age who practice rhythm, barrier or other forms of natural birth control measures which represents a significant market opportunity for QUIDEL. The issuance of this patent places QUIDEL in a strong position to provide innovative products to meet this unserved need and further extends our proprietary position in the rapid immunodiagnostic markets."
 QUIDEL Corp. develops, manufactures and markets rapid immunodiagnostic products that provide simple, accurate and cost- effective diagnoses in the areas of human fertility, allergy, infectious disease and autoimmune disorders. These tests are designed for use in the physician's office, clinical laboratory and home-testing market.
 -0- 6/17/92
 /CONTACT: Mark Francois of QUIDEL, 619-552-7931; or Susan Noonan or Anthony J. Russo of Noonan/Russo Communications, 212-979-9180, for QUIDEL/
 (QDEL) CO: QUIDEL Corp. ST: California IN: MTC SU:


EH-JL -- SD001 -- 0927 06/17/92 08:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 17, 1992
Words:387
Previous Article:TCI OF PENNSYLVANIA TO OFFER OLYMPICS 'TRIPLECAST'
Next Article:JACOBS WINS CONTRACT WITH NOVO NORDISK PHARMACEUTICAL INDUSTRIES INC.
Topics:


Related Articles
QUIDEL'S NEW ONE-STEP CONCEIVE(TM) OVULATION TEST CLEARS FDA
QUIDEL REPORTS INCREASED FOURTH QUARTER SALES AND FIRST FULL-YEAR OF PROFITABILITY
QUIDEL RECEIVES ITS SECOND PATENT FOR BIRTH CONTROL DIAGNOSTIC PRODUCT
QUIDEL REPORTS FIRST QUARTER RESULTS
QUIDEL FINALIZES FRENCH ACQUISITION
QUIDEL ACQUIRES MAJORITY INTEREST IN SPAIN'S INMUNO ANALITICA S.L.
QUIDEL UPDATES FDA SAFEPLAN(TM) STATUS
QUIDEL ACQUIRES PACIFIC BIOTECH INC. FROM ELI LILLY
QUIDEL SUBMITS RAPID CHLAMYDIA TEST TO FDA
QUIDEL RECEIVES FDA CLEARANCE FOR RAPID QUICKVUE(R) CHLAMYDIA TEST - TEST OFFERS SUPERIOR PERFORMANCE ADVANTAGES

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters